The company's goal is to enhance patient care and vascular health by continuously refining existing products and developing new technologies that reduce risk, trauma, cost, procedure time, and the need for aftercare. They have received regulatory approvals for their FA100 SCCD Sequential Contraction Compression Device in Europe, Canada, and the United States. FlowAid Medical Technologies Corp. aims to be a leader in circulatory enhancement and offers their device for various conditions such as diabetes, ulcers, neuropathy, wounds, and lymphedema.